Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma

Exclusion Criteria

• •Any disorder that compromises the ability of the patient or patient's legally acceptable representative to give written informed consent and/or to comply with the study procedures
• •Patients who will not be available for protocol required study visits, to the best of the subject and investigator's knowledge
• •History of hypersensitivity to any of the study agents (gemcitabine, docetaxel, or hydroxychloroquine) or to any component of the formulation
• •Patients who have previously received gemcitabine or docetaxel
• •Men and woman of reproductive potential, unwilling to practice a highly effective method of birth control for the duration of the study and continuing for 2 weeks (for women) and 12 weeks (for men) after receiving the last dose of study drug. Highly effective methods of birth control include sexual abstinence (men, women); vasectomy or a condom used with spermicide (men) in combination with barrier methods, hormonal birth control or intrauterine device (IUD) (women)
• •Women who are lactating/breastfeeding or planning to become pregnant during the duration of the study
• •History or current diagnosis of a second neoplasm. Exception: adequately treated non-melanoma skin cancer, curatively treated in-situ disease, or other solid tumors curatively treated with no evidence of disease for \>= 2 years
• •Myocardial infarction within 6 months of study day 1, symptomatic congestive heart failure (New York Heart Association \> class II), unstable angina, or unstable cardiac arrhythmia requiring medication, or uncontrolled hypertension (systolic \> 160 mmHg or diastolic \> 100 mmHg)
• •Active infection requiring intravenous (IV) antibiotics within 2 weeks of study enrollment
• •Significant gastrointestinal disorder(s) that in the opinion of the investigator (e.g., Crohn's disease, ulcerative colitis, extensive gastrointestinal resection) may influence drug absorption
• •Known positive test for human immunodeficiency virus (HIV)
• •Prior participation in an investigational study and/or procedure within 21 days of study day 1
• •Anti-tumor therapy within 21 days of study day 1 including chemotherapy, antibody therapy, or other investigational agent. Enrollment of subjects that have received molecularly targeted agents less than 28 days prior to study day 1 will be permitted if more than 14 days and at least 5 drug half-lives have passed prior to receiving the first dose of HCQ
• •Major surgery within 28 days of study day 1
• •Any co-morbid medical disorder that may increase the risk of toxicity, in the opinion of the investigator
• •All herbal supplements, vitamins, and nutritional supplements taken within the last 30 days prior to dosing on day 1 (and continued use, if appropriate), must be reviewed and approved by the principal investigator (PI)
• •Patients with pre-existing maculopathy or retinopathy of the eye